ピオグリタゾン トウヨ ニヨル フクブ ダイドウミャクリュウ ニオケル コウドウミャク コウカ サヨウ
Prelimenary evaluation of preoperative Pioglitazone administration on abdominal aortic aneurysm
元木, 達夫 徳島大学大学院ヘルスバイオサイエンス研究部器官修復医学講座心臓血管外科学分野
平田, 陽一郎 徳島大学大学院ヘルスバイオサイエンス研究部器官修復医学講座循環器内科学分野
Terahashi, Atsuko Department of Cardiovascular Surgery, the University of Tokushima Graduate School
吉田, 誉 徳島大学大学院ヘルスバイオサイエンス研究部器官修復医学講座心臓血管外科学分野
Accumulating evidence suggests that inflammatory cytokines secreted from visceral fat tissues potentially promote atherosclerosis progression. Recent reports suggested that pioglitazone, which is an anti-diabetes drug, reduces expression of tumor necrosis factor（TNF）‐α and ameliorates insulin-resistance in diabetic mice. Pioglitazone was also reported to suppress progression of coronary atherosclerosis. The objective of this study is to assess the effect of pioglitazone on inflammatory changes in abdominal aortic aneurysms（AAAs）. This study protocol was approved by the medical ethics committee in Tokushima University Hospital. Patients with AAA were randomized into two groups. One was with pioglitazone（Group P）. The other was without pioglitazone（Group C）. Biopsy specimens were obtained from the abdominal subcutaneous fat, the greater omentum, the retroperitoneal periaortic fat and the aneurysmal wall. Immunohistochemistry of CD ６８in those specimens was performed. The number of macrophages in Group P was lower than that in Group C. Expressions of inflammatory cytokines in those specimens were evaluated by real-time quantitative reverse transcription-polymerase chain reaction analysis. Expression of inflammatory cytokines in Group P were reduced, when compaird with those in Group C.
Our data may suggest that pioglitazone reduce inflammatory changes in human aortic aneurysm.
sam_66_3-4_91.pdf 791 KB